Back to Agenda
[S32] The Basics of Health Technology Assessment - From Clinical Trials to Pricing -
Session Chair(s)
Shunya Ikeda, PhD
Professor
International University of Health and Welfare., Japan
Followed by 2-years pilot program, HTA was newly introduced in Japan in 2018. However, the number of products evaluated in the pilot program was limited and few of employees of pharmaceutical and medical devices industries experienced actual HTA process. This session help participants understand the Japanese HTA system and think about what they need to prepare to address the requirements. The session includes the overview of basic knowledges and Japanese system of HTA by an academic expert and the review of the report of Pharmaceutical Manufacturers Association Task Force Team on the procedures of HTA. Also, experiences in HTA pilot program will be shared by each representative from pharmaceutical and medical device companies.
Speaker(s)
HTA - To Do or Not to Do, That Is the Question
Ataru Igarashi, PhD
Yokohama City University , Japan
Framework of Cost-Effectiveness Analysis
Toshihiko Aranishi, PhD
Eli Lilly Japan K.K, Japan
Research Scientist, Health Outcomes/Health Technology Assessment
The Case and Process of Pharmaceutical in Pilot Program of Cost Effectiveness Evaluation
Shinya Ohno, PhD, MPH
Chugai Pharmaceutical Co., Ltd, Japan
Director, HTA Strategy Professional
Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Japan: Experience From the Japanese Pilot Health Technology Assessment
Miyoshi Asaoka, MBA
Edwards Lifesciences Limited, Japan
Director, Health Economics & Patient Engagement, THV
Have an account?